Compare Prospect Capital Corporation (PSEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Prospect Capital Corporation trades at $1.83 (market cap $974.22M), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 10.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PSEC | XBI | |
|---|---|---|
Market Cap | $974.22M | $10.11B |
Volume | 5,779,996 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $3.05 | $169.55 |
52-Week Low | $1.82 | $104.99 |
Typical Hold Time | 78 Days | 37 Days |
Enterprise Value | $2.73B | — |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.84, up 0.55% with bearish technical signals despite recent earnings beats. The company shows inconsistent revenue trends with 2025 revenue at -$407M and net income of -$470M, though 2026 projections indicate recovery. Dividend payments continue at $0.04 monthly, while analyst sentiment remains mixed with 25% buy ratings amid concerns about NAV erosion and portfolio contraction.
PSEC presents high risk with volatile financial performance and bearish technical indicators. The 18%+ dividend yield appears unsustainable given negative cash flow and declining portfolio value. While current price represents a significant discount to book value, ongoing NAV erosion and mixed analyst consensus suggest cautious approach for investors seeking stability.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
